Live, attenuated strains of Bacillus anthracis lacking either the capsule plasmid pXO2, the toxin plasmid pXOl, or both were tested for their efficacy as vaccines against intravenous challenge with anthrax toxin in Fischer 344 rats and against aerosol or intramuscular challenge with virulent anthrax spores in Hartley guinea pigs. Animals immunized with toxigenic, nonencapsulated (pXO1, pXO2-) strains survived toxin and spore challenge and demonstrated postimmunization antibody titers to the three components of anthrax toxin (protective antigen, lethal factor, and edema factor). Immunization with two nontoxigenic, encapsulated (pXOl-, pXO2+), Pasteur vaccine strains neither provided protection nor elicited titers to any of the toxin components. Therefore, to immunize successfully against anthrax toxin or spore challenge, attenuated, live strains of B. anthracis must produce the toxin components specified by the pXOl plasmid.
Live, attenuated strains of Bacillus anthracis lacking either the capsule plasmid pXO2, the toxin plasmid pXOl, or both were tested for their efficacy as vaccines against intravenous challenge with anthrax toxin in Fischer 344 rats and against aerosol or intramuscular challenge with virulent anthrax spores in Hartley guinea pigs. Animals immunized with toxigenic, nonencapsulated (pXO1, pXO2-) strains survived toxin and spore challenge and demonstrated postimmunization antibody titers to the three components of anthrax toxin (protective antigen, lethal factor, and edema factor). Immunization with two nontoxigenic, encapsulated (pXOl-, pXO2+), Pasteur vaccine strains neither provided protection nor elicited titers to any of the toxin components. Therefore, to immunize successfully against anthrax toxin or spore challenge, attenuated, live strains of B. anthracis must produce the toxin components specified by the pXOl plasmid.
Virulent strains of Bacillus anthracis possess two virulence factors (22) : a poly-D-glutamic acid capsule (11) and a tripartite exotoxin (1, 24) , which consists of protective antigen (PA), edema factor (EF), and lethal factor (LF). Production of the toxin is controlled by a 110-megadalton plasmid, pXO1 (formerly called pBA1) (17) , and synthesis of the capsule is dependent on a 60-megadalton plasmid, pXO2 (7, 27) . Thus, fully virulent strains (pXO1+, pXO2+) produce both toxin and capsule; pXO1+, pXO2-strains produce toxin only; pXO1-, pXO2+ strains produce capsule only; and pXO1-, pXO2-strains produce neither toxin nor capsule (7) .
In the United States, the currently licensed human vaccine against anthrax (in this report designated MDPH-PA) consists of aluminum hydroxide-adsorbed culture supernatant material, primarily PA (9), from a toxigenic, nonencapsulated strain of B. anthracis, V770-NP1-R (19) . Immunization with this vaccine requires a series of six doses over an 18-month period, followed by boosters at yearly intervals. For immunization of livestock against anthrax, a suspension of viable spores of the toxigenic, nonencapsulated Sterne strain is commonly used (26) .
The first anthrax vaccines that were widely used for livestock during the late 1800s and early 1900s were the Pasteur-type vaccines (17, 29, 30) , which consisted of cultures of virulent anthrax bacilli attenuated by growth at 42 to 43°C. Unfortunately, these vaccines varied greatly in their degree of attenuation (29, 30) . Some cultures were sufficiently virulent to kill the animals inoculated (13), while others were so attenuated that they conferred no immunity (29, 30 ). An explanation for the molecular mechanism of attenuation of Pasteur- was recorded, and the harmonic mean TTD was calculated. Serological studies. PA, EF, and LF were purified from R medium culture supernatants of B. anthracis Sterne as previously described (14) . Antibody titers in postimmunization sera from rats and guinea pigs were determined for antibody against the three toxin components by enzymelinked immunosorbent assay (ELISA). For the assays, microtiter plate (Linbro) wells were coated with PA, EF, or LF (100 j.l of a 1-,ug/ml solution in 0.05 M sodium borate, pH 9.5). After incubation for 4 h at 37°C or overnight at 4°C, 160 ,u1 of either bovine serum albumin or gelatin (1 mg/ml in 5 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid]-0.15 M NaCl, pH 7.5) was added to each well, and the plates were reincubated for 30 min at 25°C. The wells were washed twice with 300 ,ul of PBST (0.85% sodium chloride, 10 mM sodium phosphate, 0.05% Tween 20 (28) . The mean titers of sera from immunized animals compared with those from unimmunized controls were statistically analyzed by one-way analysis of variance and Fisher's least significant difference test (25) .
To demonstrate that animals vaccinated with the various attenuated strains had received sufficient antigenic stimulus to engender an immune response, postvaccination sera from the guinea pigs were examined for activity in a B. anthracis whole-cell ELISA system. Experimental conditions were identical to those described above, with two exceptions: (i) 107 log-phase Sterne strain cells in PBS were added to each well of a 96-well tissue culture plate (Costar) that was then dried overnight at 25°C and heated to 60°C for 30 min to fix the cells to the wells; and (ii) rather than serial dilutions, a single 1:4 dilution of each serum sample was assayed. ELISA absorbance values for serum samples from vaccinated animals were compared with values for sera from unvaccinated control animals. Statistical analyses were performed as described above. RESULTS Immunization of rats against toxin challenge. Fischer 344 rats are the most anthrax toxin-sensitive animals known (1, 6, 8) . When these rats were immunized with Sterne (pXO1+, pXO2-) strain bacteria, they were completely protected from lethal toxicity and exhibited significant titers to PA, LF, and EF (P < 0.05) ( the EF and LF components on the immunizing efficacy of the MDPH-PA vaccine as well as the efficacy of pure PA as an immunogen remains unknown. Clearly, however, these two questions must be resolved before any new human vaccine is developed. The-protection and serological studies we report here indicate that to protect animals against a large anthrax toxin or spore challenge, one or more toxin components must be present in a chemical vaccine or produced by a live vaccine. The finding that vaccination with pXO1-, pXO2+ B. anthracis strains, which produce capsule but not toxin, was not protective supports previous reports that the D-glutamyl polypeptide capsule of the organism is not an important immunogen (10, 23) . The finding, however, does not explain how Pasteur's heat attenuation regimen, which causes the selective loss of pXO1 (7, 17) , produced a successful live anthrax vaccine. It does emphasize the apparent paradox between Pasteur's original vaccine strains and the Pasteurtype strains available from the American Type Culture Collection, which are completely ineffective as immunogens. The current hypothesis to explain Louis Pasteur's mechanism of attenuation of B. anthracis is that by growing virulent cells at high temperatures, he induced the loss of the pXO1 toxin plasmid (17) , resulting in an increased proportion of pXO1-, pXO2+ cells and a decreased proportion of virulent pXO1+, pXO2+ cells in the cultures. Since our studies have clearly demonstrated that pure cultures of pXO1-, pXO2+ B. anthracis cells are not effective live vaccines, we believe that the efficacy of Pasteur's vaccines can be attributed to the presence of small numbers of pXO1+, pXO2+ bacteria and that subclinical infection by these bacteria would have induced a protective immune response. Evidence that Pasteur's vaccine did indeed contain virulent cells was provided by Pasteur himself. He demonstrated that serial passage of the attenuated cultures through day-old guinea pigs restored virulence (5), apparently by selecting for the virulent bacilli present. The fact that the Pasteur-type strains from the American Type Culture Collection contain only the pXO2 plasmid (7), whereas those from the Japanese collection contain both plasmids (27) , must reflect the different results obtained when pure culture technique was applied to Pasteur's mixed cultures without recognition that a mixture was present.
